Vincent Patrice, Lucas de Couville Thibaut, Thomas Thierry
LCA Pharmaceutical, Chartres, France.
Department of Rheumatology, University Hospital Centre, St Etienne, France.
Curr Ther Res Clin Exp. 2020 Feb 26;92:100575. doi: 10.1016/j.curtheres.2020.100575. eCollection 2020.
Intra-articular injections of hyaluronic acid-also called viscosupplementation (VS)-is frequently used for the symptomatic treatment of knee osteoarthritis, a painful and debilitating long-term disease, affecting an important fraction of elderly populations. Severity of knee osteoarthritis is generally described by Kellgren-Lawrence (KL) radiological classification. VS has been widely studied in many clinical trials; however, the results are rarely analyzed in detail according to KL grade.
A large, clinical, open-label study was performed in 2004-2007 on 1177 patients with knee osteoarthritis, each treated with VS consisting of 3 injections of Arthrum H 2% (LCA Pharmaceutical, Chartres, France). The characteristics of the patients at baseline included demographic profile, body mass index, KL grade, and clinical scores for pain and function using the Western Ontario and McMaster Universities index. Follow-up visits were at 3, 6, and 9 months after VS procedure. This large database was entirely reprocessed in 2019 to provide a separate analysis per KL grade, complemented by the assessment of the Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International rates (%) of responders to the treatment. The analysis was carried out for both intention-to-treat and per-protocol completer populations.
A primary outcome in the intention-to-treat analysis, variations of the Western Ontario and McMaster Universities index pain subscore from inclusion to the end of the study were 19.8, 19.8, 17.8, and 14.2 for KL grade I to KL grade IV patients, respectively, on a 0 to 100 scale. In the per-protocol analysis, under the same conditions, the variations were 20.6, 19.9, 17.1, and 11.7. All results were significant ( < 0.001) and clinically relevant for each KL grade. Significant improvements were also observed for the Western Ontario and McMaster Universities index function subscore and for the other secondary outcomes. The Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International responders rate reached 72% to 82% for KL grade I through III patients at Month 6 and Month 9. For KL grade IV patients, the maximum rate reached was 47.7% at Month 6. There was evidence that KL grade is a critical parameter, particularly if KL grade IV is present. Other parameters such as gender, body mass index, and age were not identified as prognostic factors of response to VS based on χ and odds ratio (95% CI) testing.
Detailed analysis by KL grade supports that VS treatment with Arthrum H 2% applies to a large variety of patients with knee osteoarthritis.
关节腔内注射透明质酸——也称为粘弹性补充疗法(VS)——常用于膝关节骨关节炎的对症治疗,这是一种疼痛且使人衰弱的长期疾病,影响着很大一部分老年人群。膝关节骨关节炎的严重程度通常通过凯尔格伦-劳伦斯(KL)放射学分类来描述。VS已在许多临床试验中得到广泛研究;然而,结果很少根据KL分级进行详细分析。
2004年至2007年对1177例膝关节骨关节炎患者进行了一项大型开放性临床研究,每位患者均接受了由3次注射2% Arthrum H(法国沙特尔的LCA制药公司生产)组成的VS治疗。基线时患者的特征包括人口统计学资料、体重指数、KL分级以及使用西安大略和麦克马斯特大学指数的疼痛和功能临床评分。随访在VS治疗后的3个月、6个月和9个月进行。2019年对这个大型数据库进行了全面重新处理,以按KL分级进行单独分析,并辅以类风湿关节炎临床试验-骨关节炎研究协会国际组织治疗反应者结局测量率(%)的评估。对意向性治疗人群和符合方案完成者人群均进行了分析。
在意向性治疗分析的主要结局中,从纳入研究到研究结束,西安大略和麦克马斯特大学指数疼痛子评分的变化在0至100分的量表上,KL I级至KL IV级患者分别为19.8、19.8、17.8和14.2。在符合方案分析中,在相同条件下,变化分别为20.6、19.9、17.1和11.7。所有结果均具有显著性(<0.001),且对每个KL分级均具有临床相关性。西安大略和麦克马斯特大学指数功能子评分以及其他次要结局也观察到了显著改善。类风湿关节炎临床试验-骨关节炎研究协会国际组织治疗反应者率在第6个月和第9个月时,KL I级至III级患者达到72%至82%。对于KL IV级患者,在第6个月时最高率达到47.7%。有证据表明KL分级是一个关键参数,特别是当存在KL IV级时。基于χ检验和优势比(95%CI)测试,未将性别、体重指数和年龄等其他参数确定为VS治疗反应的预后因素。
按KL分级进行的详细分析支持,使用2% Arthrum H进行的VS治疗适用于多种膝关节骨关节炎患者。